Recent progress in the pathophysiology and treatment of FSGS recurrence.
about
Update on the treatment of focal segmental glomerulosclerosis in renal transplantationFSGS Recurrence in Adults after Renal TransplantationThe Impact of Histologic Variants on FSGS OutcomesCitral is renoprotective for focal segmental glomerulosclerosis by inhibiting oxidative stress and apoptosis and activating Nrf2 pathway in miceBone marrow-derived immature myeloid cells are a main source of circulating suPAR contributing to proteinuric kidney disease.Rare inherited kidney diseases: challenges, opportunities, and perspectives.Heterogeneous genetic alterations in sporadic nephrotic syndrome associate with resistance to immunosuppressionThe role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series.Treatment of Focal Segmental Glomerulosclerosis Recurrence in the Renal Allograft: A Report of Two CasesRecurrent Primary Focal Segmental Glomerulosclerosis Managed With Intensified Plasma Exchange and Concomitant Monitoring of Soluble Urokinase-Type Plasminogen Activator Receptor-Mediated Podocyte β3-integrin ActivationCirculating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot studyImmunopathogenesis of idiopathic nephrotic syndrome with relapse.Recurrent focal segmental glomerulosclerosis after kidney transplantation.Extrarenal determinants of kidney filter function.The importance of non-HLA antibodies in transplantation.Optimal management of primary focal segmental glomerulosclerosis in adultsRole of race in kidney transplant outcomes in children with focal segmental glomerulosclerosis.Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis.Complement in Non-Antibody-Mediated Kidney Diseases.Unsuccessful Treatment with Abatacept in Recurrent Focal Segmental Glomerulosclerosis after Kidney Transplantation.B7-1 Blockade Does Not Improve Post-Transplant Nephrotic Syndrome Caused by Recurrent FSGS.Racial disparities in pediatric kidney transplantation in New Zealand.Success with plasmapheresis treatment for recurrent focal segmental glomerulosclerosis in pediatric renal transplant recipients.Recurrence of primary glomerulonephritis: Review of the current evidence.Recurrence of primary glomerulonephritis: Review of the current evidence.Treatment by immunoadsorption for recurrent focal segmental glomerulosclerosis after paediatric kidney transplantation: a multicentre French cohort.Recurrent and de novo glomerulonephritis following renal transplantation: higher rates of rejection and lower graft survival.Recurrent FSGS Postkidney Transplant: Moving the Needle Forward.Proteinuria: abate or applaud abatacept in proteinuric kidney disease?Application of next-generation sequencing technology to diagnosis and treatment of focal segmental glomerulosclerosis.A case of recurrent focal segmental glomerulosclerosis after kidney transplantation associated with variant conversion in the Columbia classification.
P2860
Q26751470-9B1F5732-34F0-4D42-AE24-5A11A7135E1CQ26752840-B4C6A377-366A-42AD-8078-FB5DDAC163DAQ27011243-4D44CBB4-2B5E-4591-8525-1B0B7E970D5FQ28533529-B2788BEE-37D7-471C-93B3-CF286DBDCC8FQ33605113-C3799F3B-F0A6-4A35-B152-34A73AF4F141Q34054113-C539D512-6668-4C40-B9E7-5FB459DBAD03Q34787771-E13ED57F-FCE3-4279-B090-2913A0A1B0FEQ36090317-8BA99797-B728-40CB-82B8-097C9A2F26B2Q36811343-FB923B15-9AA5-4004-B636-5C74D95AD592Q36987307-1B19C8E1-4137-40F4-B74C-636D28B593F9Q36994919-12B2E3E2-237E-4770-ACE6-964555955270Q37742644-71B38D06-C2A5-4C68-B9CD-BCD2E156C355Q38359297-3F46FE4C-3362-420C-A597-58AA2C10B796Q38754939-78A32D13-9ADC-4D75-918F-A250CBF74D1DQ38877375-00ACCD0B-DAE9-442F-9894-97A2FDBC6B7CQ39331611-61C94832-2BC0-48F5-83A9-CAB9B1C9943BQ39557822-99C1D8DF-09E1-47A1-AF72-CC3EEA7750DCQ39815667-6BC6619D-4EC0-4CE0-A821-0EBF5159942BQ40986583-E3476AE5-46AF-41F7-B53A-B6C1260BEA7AQ42322601-B1475014-B167-4B84-8644-CCC68D101263Q42371173-38E29A2B-4C16-400A-B506-AA1B025939CBQ43728035-D56D4083-EC6F-4DE5-AB4C-48467A0FC815Q46171879-3CBC365E-D699-4056-ACF8-6359AFAB1BEBQ47193282-B1BB9654-8364-4DFB-BFF0-80B9AC2849C2Q47243136-FD1F09D5-362F-4DC3-959D-2E2DEECE9136Q47676776-298DBAC1-5F68-4524-80EA-DC224D668857Q47803778-396B7529-73A8-4054-BDF8-E96D5E8A029BQ50294330-66090394-1F41-4F09-B926-D8F074B5B7CFQ51762915-B6867A59-6C60-4E39-9706-86D76BA81B78Q52561530-0B1C7734-3786-40DA-B4B3-6BC02CE8C446Q53482943-2A88430C-C692-4E9F-86CC-1735202C50F1
P2860
Recent progress in the pathophysiology and treatment of FSGS recurrence.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@ast
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@en
type
label
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@ast
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@en
prefLabel
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@ast
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@en
P2860
P356
P1476
Recent progress in the pathophysiology and treatment of FSGS recurrence.
@en
P2093
P2860
P304
P356
10.1111/AJT.12045
P407
P577
2013-01-11T00:00:00Z